analysts said that the deal is aimed at offsetting johnson johnson's reliance on a slowing drug business.meanwhile, demand for defibrillators, which give the heart a small electric shock when an irregular heartbeat or rhythm is detected, is expected to increase, analysts said.analysts say that us antitrust regulators could force the firms to shed some overlapping stent operations.